Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DT2216 in Relapsed/Refractory Malignancies
NCT04886622Phase 1Completed
- Sponsor
- Dialectic Therapeutics, Inc.
- Start
- Aug 2021
- Primary completion
- Jun 2024
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DT2216 in solid tumor and hematologic malignancy, sponsored by Dialectic Therapeutics, Inc. Primary endpoints: Number of participants with adverse events at 28 days and Dose Limiting Toxicity at 28 days. Started Aug 2021; status: completed.
02
Drugs
DT2216
03
Conditions
solid tumorhematologic malignancy
Beyond the preview
Go deeper on NCT04886622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04886622.